;PMID: 8331551
;source_file_855.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..42] = [t:0..42]
;1)sentence:[e:48..243] = [t:48..243]
;2)section:[e:247..296] = [t:247..296]
;3)section:[e:300..368] = [t:300..368]
;4)sentence:[e:372..652] = [t:372..652]
;5)sentence:[e:653..963] = [t:653..963]
;6)sentence:[e:964..1186] = [t:964..1186]
;7)sentence:[e:1187..1337] = [t:1187..1337]
;8)sentence:[e:1338..1550] = [t:1338..1550]
;9)sentence:[e:1551..1638] = [t:1551..1638]
;10)sentence:[e:1639..1720] = [t:1639..1720]
;11)sentence:[e:1721..1838] = [t:1721..1838]
;12)sentence:[e:1840..2058] = [t:1840..2058]
;13)section:[e:2062..2106] = [t:2062..2106]

;section 0 Span:0..42
;J Pharmacol Exp Ther. 1993 Jul;266(1):1-7.
(SEC
  (FRAG (NNP:[0..1] J) (NNP:[2..11] Pharmacol) (NNP:[12..15] Exp)
        (NNP:[16..20] Ther) (.:[20..21] .) (CD:[22..26] 1993)
        (CC:[27..35] Jul;266-LRB-) (CD:[35..36] 1) (-RRB-:[36..37] -RRB-)
        (CD:[37..39] :1) (::[39..40] -) (CD:[40..42] 7.)))

;sentence 1 Span:48..243
;Involvement of cytochrome P-450IIIA in metabolism of potassium canrenoate to
;an  epoxide: mechanism of inhibition of the epoxide formation by
;spironolactone and  its sulfur-containing metabolite.
;[63..83]:cyp450:"cytochrome P-450IIIA"
;[101..121]:substance:"potassium canrenoate"
;[129..136]:substance:"epoxide"
;[169..176]:substance:"epoxide"
;[190..204]:substance:"spironolactone"
;[214..220]:substance:"sulfur"
;[232..242]:substance:"metabolite"
(SENT
  (NP-HLN
    (NP
      (NP (NN:[48..59] Involvement))
      (PP (IN:[60..62] of)
        (NP (NN:[63..73] cytochrome) (NN:[74..83] P-450IIIA)))
      (PP (IN:[84..86] in)
        (NP
          (NP (NN:[87..97] metabolism))
          (PP (IN:[98..100] of)
            (NP (NN:[101..110] potassium) (NN:[111..121] canrenoate)))
          (PP (TO:[122..124] to)
            (NP (DT:[125..127] an) (NN:[129..136] epoxide))))))
    (::[136..137] :)
    (NP
      (NP (NN:[138..147] mechanism))
      (PP (IN:[148..150] of)
        (NP
          (NP (NN:[151..161] inhibition))
          (NP (IN:[162..164] of)
            (NP (DT:[165..168] the) (NN:[169..176] epoxide)
                (NN:[177..186] formation)))
          (PP-MNR (IN:[187..189] by)
            (NP
              (NP (NN:[190..204] spironolactone))
              (CC:[205..208] and)
              (NP (PRP$:[210..213] its)
                (ADJP (NN:[214..220] sulfur) (HYPH:[220..221] -)
                      (VBG:[221..231] containing))
                (NN:[232..242] metabolite)))))))
    (.:[242..243] .)))

;section 2 Span:247..296
;Cook CS, Hauswald C, Oppermann JA, Schoenhard GL.
(SEC
  (FRAG (NNP:[247..251] Cook) (NNP:[252..254] CS) (NNP:[254..255] ,)
        (NNP:[256..264] Hauswald) (NNP:[265..266] C) (,:[266..267] ,)
        (NNP:[268..277] Oppermann) (NNP:[278..280] JA) (,:[280..281] ,)
        (NNP:[282..292] Schoenhard) (NNP:[293..296] GL.)))

;section 3 Span:300..368
;Department of Drug Metabolism, G. D. Searle & Co., Skokie, Illinois.
(SEC
  (FRAG (NNP:[300..310] Department) (IN:[311..313] of) (NNP:[314..318] Drug)
        (NNP:[319..329] Metabolism) (,:[329..330] ,) (NNP:[331..333] G.)
        (NNP:[334..336] D.) (NNP:[337..343] Searle) (CC:[344..345] &)
        (NNP:[346..349] Co.) (,:[349..350] ,) (NNP:[351..357] Skokie)
        (,:[357..358] ,) (NNP:[359..367] Illinois) (.:[367..368] .)))

;sentence 4 Span:372..652
;In vitro metabolism studies of potassium canrenoate (PC) were conducted to 
;examine whether spironolactone (SP) and/or its sulfur-containing metabolites 
;inhibit the PC metabolic pathways to mutagenic metabolites and to elucidate
;the  mechanism for any observed inhibitory effect.
;[403..423]:substance:"potassium canrenoate"
;[425..427]:substance:"PC"
;[464..478]:substance:"spironolactone"
;[480..482]:substance:"SP"
;[495..501]:substance:"sulfur"
;[513..524]:substance:"metabolites"
;[538..540]:substance:"PC"
;[573..584]:substance:"metabolites"
(SENT
  (S
    (NP-SBJ-1
      (NP
        (ADJP (FW:[372..374] In) (FW:[375..380] vitro))
        (NN:[381..391] metabolism) (NNS:[392..399] studies))
      (PP (IN:[400..402] of)
        (NP
          (NP (NN:[403..412] potassium) (NN:[413..423] canrenoate))
          (NP (-LRB-:[424..425] -LRB-) (NN:[425..427] PC)
              (-RRB-:[427..428] -RRB-)))))
    (VP (VBD:[429..433] were)
      (VP (VBN:[434..443] conducted)
        (NP-1 (-NONE-:[443..443] *))
        (S-PRP
          (S
            (NP-SBJ (-NONE-:[443..443] *))
            (VP
              (VP (TO:[444..446] to)
                (VP (VB:[448..455] examine)
                  (SBAR (IN:[456..463] whether)
                    (S
                      (NP-SBJ
                        (NP
                          (NP (NN:[464..478] spironolactone))
                          (NP (-LRB-:[479..480] -LRB-) (NN:[480..482] SP)
                              (-RRB-:[482..483] -RRB-)))
                        (CC:[484..490] and/or)
                        (NP (PRP$:[491..494] its)
                          (ADJP (NN:[495..501] sulfur) (HYPH:[501..502] -)
                                (VBG:[502..512] containing))
                          (NNS:[513..524] metabolites)))
                      (VP (VBP:[526..533] inhibit)
                        (NP
                          (NP (DT:[534..537] the) (NN:[538..540] PC)
                              (JJ:[541..550] metabolic)
                              (NNS:[551..559] pathways))
                          (PP (TO:[560..562] to)
                            (NP (JJ:[563..572] mutagenic)
                                (NNS:[573..584] metabolites)))))))))
              (CC:[585..588] and)
              (VP (TO:[589..591] to)
                (VP (VB:[592..601] elucidate)
                  (NP (DT:[602..605] the) (NN:[607..616] mechanism))
                  (PP (IN:[617..620] for)
                    (NP (DT:[621..624] any) (JJ:[625..633] observed)
                        (JJ:[634..644] inhibitory) (NN:[645..651] effect))))))))))
    (.:[651..652] .)))

;sentence 5 Span:653..963
;The mechanistic study was  conducted using liver microsomes prepared from
;male and female rats with and  without pretreatment of a cytochrome (Cyt)
;P-450IIIA inducer [pregnenolone-16  alpha-carbonitrile (PCN) or dexamethasone
;(DEX)] and with and without a Cyt  P-450IIIA inhibitor, triacetyloleandomycin
;(TAO).
;[784..810]:cyp450:"cytochrome (Cyt) P-450IIIA"
;[811..818]:substance:"inducer"
;[820..855]:substance:"pregnenolone-16  alpha-carbonitrile"
;[857..860]:substance:"PCN"
;[865..878]:substance:"dexamethasone"
;[880..883]:substance:"DEX"
;[909..923]:cyp450:"Cyt  P-450IIIA"
;[924..933]:substance:"inhibitor"
;[935..956]:substance:"triacetyloleandomycin"
;[958..961]:substance:"TAO"
(SENT
  (S
    (NP-SBJ-4 (DT:[653..656] The) (JJ:[657..668] mechanistic)
              (NN:[669..674] study))
    (VP (VBD:[675..678] was)
      (VP (VBN:[680..689] conducted)
        (NP-4 (-NONE-:[689..689] *))
        (S-MNR
          (NP-SBJ (-NONE-:[689..689] *))
          (VP (VBG:[690..695] using)
            (NP
              (NP (NN:[696..701] liver) (NNS:[702..712] microsomes))
              (VP (VBN:[713..721] prepared)
                (NP (-NONE-:[721..721] *))
                (PP (IN:[722..726] from)
                  (NP
                    (NP (JJ:[727..731] male)
                      (NML-3 (-NONE-:[731..731] *P*)))
                    (CC:[732..735] and)
                    (NP (JJ:[736..742] female)
                      (NML-3 (NNS:[743..747] rats)))))
                (PP
                  (PP (IN:[748..752] with) (CC:[753..756] and)
                      (IN:[758..765] without)
                    (NP
                      (NP (NN:[766..778] pretreatment))
                      (PP (IN:[779..781] of)
                        (NP
                          (NP (DT:[782..783] a)
                            (NML
                              (NML
                                (NML (NN:[784..794] cytochrome))
                                (NML (-LRB-:[795..796] -LRB-)
                                     (NN:[796..799] Cyt)
                                     (-RRB-:[799..800] -RRB-)))
                              (NN:[801..810] P-450IIIA))
                            (NN:[811..818] inducer))
                          (PRN (-LRB-:[819..820] -LSB-)
                            (NP
                              (NP
                                (NP (NN:[820..835] pregnenolone-16)
                                    (NN:[837..855] alpha-carbonitrile))
                                (NP (-LRB-:[856..857] -LRB-) (NN:[857..860] PCN)
                                    (-RRB-:[860..861] -RRB-)))
                              (CC:[862..864] or)
                              (NP
                                (NP (NN:[865..878] dexamethasone))
                                (NP (-LRB-:[879..880] -LRB-) (NN:[880..883] DEX)
                                    (-RRB-:[883..884] -RRB-))))
                            (-RRB-:[884..885] -RSB-))))))
                  (CC:[886..889] and)
                  (PP (IN:[890..894] with) (CC:[895..898] and)
                      (IN:[899..906] without)
                    (NP
                      (NP (DT:[907..908] a)
                         (NN:[909..912] Cyt) (NN:[914..923] P-450IIIA)
                        (NN:[924..933] inhibitor))
                      (,:[933..934] ,)
                      (NP
                        (NP (NN:[935..956] triacetyloleandomycin))
                        (NP (-LRB-:[957..958] -LRB-) (NN:[958..961] TAO)
                            (-RRB-:[961..962] -RRB-))))))))))))
    (.:[962..963] .)))

;sentence 6 Span:964..1186
;The present study demonstrates  that SP and its sulfur-containing metabolite
;7 alpha-thio-spirolactone  substantially inhibited the formation of
;promutagen 6 beta, 7  beta-epoxycanrenone (6 beta, 7 beta-epoxy-CAN) from
;PC.
;[1001..1003]:substance:"SP"
;[1012..1018]:substance:"sulfur"
;[1030..1040]:substance:"metabolite"
;[1041..1066]:substance:"7 alpha-thio-spirolactone"
;[1109..1119]:substance:"promutagen"
;[1120..1150]:substance:"6 beta, 7  beta-epoxycanrenone"
;[1152..1176]:substance:"6 beta, 7 beta-epoxy-CAN"
;[1183..1185]:substance:"PC"
(SENT
  (S
    (NP-SBJ (DT:[964..967] The) (JJ:[968..975] present) (NN:[976..981] study))
    (VP (VBZ:[982..994] demonstrates)
      (SBAR (IN:[996..1000] that)
        (S
          (NP-SBJ-1
            (NP (NN:[1001..1003] SP))
            (CC:[1004..1007] and)
            (NP
              (NP (PRP$:[1008..1011] its)
                (ADJP (NN:[1012..1018] sulfur) (HYPH:[1018..1019] -)
                      (VBG:[1019..1029] containing))
                (NN:[1030..1040] metabolite))
              (NP (CD:[1041..1042] 7) (NN:[1043..1066] alpha-thio-spirolactone))))
          (ADVP (RB:[1068..1081] substantially))
          (VP (VBD:[1082..1091] inhibited)
            (NP
              (NP (DT:[1092..1095] the) (NN:[1096..1105] formation))
              (PP (IN:[1106..1108] of)
                (NP (NN:[1109..1119] promutagen)
                  (NML
                    (NML (CD:[1120..1121] 6) (SYM:[1122..1126] beta)
                         (,:[1126..1127] ,) (CD:[1128..1129] 7)
                         (NN:[1131..1150] beta-epoxycanrenone))
                    (NML (-LRB-:[1151..1152] -LRB-)
                       (CD:[1152..1153] 6) (SYM:[1154..1158] beta)
                       (,:[1158..1159] ,) (CD:[1160..1161] 7)
                       (NN:[1162..1176] beta-epoxy-CAN)
                      (-RRB-:[1176..1177] -RRB-)))))
              (PP (IN:[1178..1182] from)
                (NP (NN:[1183..1185] PC))))))))
    (.:[1185..1186] .)))

;sentence 7 Span:1187..1337
;The sulfur-containing  metabolite of SP that inhibit promutagen formation
;were not formed from PC,  although a glutathione conjugate of PC was formed.
;[1191..1197]:substance:"sulfur"
;[1210..1220]:substance:"metabolite"
;[1224..1226]:substance:"SP"
;[1240..1250]:substance:"promutagen"
;[1282..1284]:substance:"PC"
;[1298..1319]:substance:"glutathione conjugate"
;[1323..1325]:substance:"PC"
(SENT
  (S
    (NP-SBJ-3
      (NP
        (NP (DT:[1187..1190] The)
          (ADJP (NN:[1191..1197] sulfur) (HYPH:[1197..1198] -)
                (VBG:[1198..1208] containing))
          (NN:[1210..1220] metabolite))
        (PP (IN:[1221..1223] of)
          (NP (NN:[1224..1226] SP))))
      (SBAR
        (WHNP-2 (WDT:[1227..1231] that))
        (S
          (NP-SBJ-2 (-NONE-:[1231..1231] *T*))
          (VP (VBP:[1232..1239] inhibit)
            (NP (NN:[1240..1250] promutagen) (NN:[1251..1260] formation))))))
    (VP (VBD:[1261..1265] were) (RB:[1266..1269] not)
      (VP (VBN:[1270..1276] formed)
        (NP-3 (-NONE-:[1276..1276] *))
        (PP (IN:[1277..1281] from)
          (NP (NN:[1282..1284] PC)))))
    (,:[1284..1285] ,)
    (SBAR-ADV (IN:[1287..1295] although)
      (S
        (NP-SBJ-1
          (NP (DT:[1296..1297] a)
             (NN:[1298..1309] glutathione) (NN:[1310..1319] conjugate))
          (PP (IN:[1320..1322] of)
            (NP (NN:[1323..1325] PC))))
        (VP (VBD:[1326..1329] was)
          (VP (VBN:[1330..1336] formed)
            (NP-1 (-NONE-:[1336..1336] *))))))
    (.:[1336..1337] .)))

;sentence 8 Span:1338..1550
;The formation rate of 6 beta,  7 beta-epoxy-CAN was greater in liver
;microsomes prepared from rats pretreated  with a Cyt P-450IIIA inducer (PCN
;or DEX) than in liver microsomes prepared from  the untreated rats.
;[1360..1385]:substance:"6 beta,  7 beta-epoxy-CAN"
;[1456..1469]:cyp450:"Cyt P-450IIIA"
;[1470..1477]:substance:"inducer"
;[1479..1482]:substance:"PCN"
;[1486..1489]:substance:"DEX"
(SENT
  (S
    (NP-SBJ
      (NP (DT:[1338..1341] The) (NN:[1342..1351] formation)
          (NN:[1352..1356] rate))
      (PP (IN:[1357..1359] of)
        (NP (CD:[1360..1361] 6) (SYM:[1362..1366] beta) (,:[1366..1367] ,)
            (CD:[1369..1370] 7) (NN:[1371..1385] beta-epoxy-CAN))))
    (VP (VBD:[1386..1389] was)
      (ADJP-PRD
        (ADJP (JJR:[1390..1397] greater))
        (PP-1 (-NONE-:[1397..1397] *ICH*)))
      (PP-LOC (IN:[1398..1400] in)
        (NP
          (NP (NN:[1401..1406] liver) (NNS:[1407..1417] microsomes))
          (VP (VBN:[1418..1426] prepared)
            (NP (-NONE-:[1426..1426] *))
            (PP (IN:[1427..1431] from)
              (NP
                (NP (NNS:[1432..1436] rats))
                (VP (VBN:[1437..1447] pretreated)
                  (NP (-NONE-:[1447..1447] *))
                  (PP-MNR (IN:[1449..1453] with)
                    (NP
                      (NP (DT:[1454..1455] a)
                        (NML (NN:[1456..1459] Cyt) (NN:[1460..1469] P-450IIIA))
                        (NN:[1470..1477] inducer))
                      (PRN (-LRB-:[1478..1479] -LRB-)
                        (NP (NN:[1479..1482] PCN) (CC:[1483..1485] or)
                            (NN:[1486..1489] DEX))
                        (-RRB-:[1489..1490] -RRB-))))))))))
      (PP-1 (IN:[1491..1495] than)
        (PP-LOC (IN:[1496..1498] in)
          (NP
            (NP (NN:[1499..1504] liver) (NNS:[1505..1515] microsomes))
            (VP (VBN:[1516..1524] prepared)
              (NP (-NONE-:[1524..1524] *))
              (PP (IN:[1525..1529] from)
                (NP (DT:[1531..1534] the) (JJ:[1535..1544] untreated)
                    (NNS:[1545..1549] rats))))))))
    (.:[1549..1550] .)))

;sentence 9 Span:1551..1638
;The formation rate of the epoxide metabolite was lower after  in vitro
;addition of TAO.
;[1577..1595]:substance:"epoxide metabolite"
;[1634..1637]:substance:"TAO"
(SENT
  (S
    (NP-SBJ
      (NP (DT:[1551..1554] The) (NN:[1555..1564] formation)
          (NN:[1565..1569] rate))
      (PP (IN:[1570..1572] of)
        (NP (DT:[1573..1576] the)
           (NN:[1577..1584] epoxide) (NN:[1585..1595] metabolite))))
    (VP (VBD:[1596..1599] was)
      (ADJP-PRD (JJR:[1600..1605] lower))
      (PP-TMP (IN:[1606..1611] after)
        (NP
          (NP
            (ADJP (FW:[1613..1615] in) (FW:[1616..1621] vitro))
            (NN:[1622..1630] addition))
          (PP (IN:[1631..1633] of)
            (NP (NN:[1634..1637] TAO))))))
    (.:[1637..1638] .)))

;sentence 10 Span:1639..1720
;Pretreatment of animals with TAO 4 hr before sacrifice  produced similar
;results.
;[1668..1671]:substance:"TAO"
;[1672..1673]:quantitative-value:"4"
;[1674..1676]:quantitative-units:"hr"
(SENT
  (S
    (NP-SBJ
      (NP (NN:[1639..1651] Pretreatment))
      (PP (IN:[1652..1654] of)
        (NP (NNS:[1655..1662] animals)))
      (PP (IN:[1663..1667] with)
        (NP (NN:[1668..1671] TAO)))
      (PP-TMP
        (NP-ADV (CD:[1672..1673] 4) (NN:[1674..1676] hr))
        (IN:[1677..1683] before)
        (NP (NN:[1684..1693] sacrifice))))
    (VP (VBD:[1695..1703] produced)
      (NP (JJ:[1704..1711] similar) (NNS:[1712..1719] results)))
    (.:[1719..1720] .)))

;sentence 11 Span:1721..1838
;Erythromycin, which is N-demethylated by Cyt  P-450IIIA, also reduced the
;formation rate of 6 beta, 7 beta-epoxy-CAN.
;[1721..1733]:substance:"Erythromycin"
;[1762..1776]:cyp450:"Cyt  P-450IIIA"
;[1813..1837]:substance:"6 beta, 7 beta-epoxy-CAN"
(SENT
  (S
    (NP-SBJ
      (NP (NN:[1721..1733] Erythromycin))
      (,:[1733..1734] ,)
      (SBAR
        (WHNP-1 (WDT:[1735..1740] which))
        (S
          (NP-SBJ-1 (-NONE-:[1740..1740] *T*))
          (VP (VBZ:[1741..1743] is)
            (VP (NN:[1744..1745] N) (HYPH:[1745..1746] -)
                (VBN:[1746..1758] demethylated)
              (NP-1 (-NONE-:[1758..1758] *))
              (PP (IN:[1759..1761] by)
                (NP-LGS (NN:[1762..1765] Cyt) (NN:[1767..1776] P-450IIIA))))))))
    (,:[1776..1777] ,)
    (VP
      (ADVP (RB:[1778..1782] also))
      (VBD:[1783..1790] reduced)
      (NP
        (NP (DT:[1791..1794] the) (NN:[1795..1804] formation)
            (NN:[1805..1809] rate))
        (PP (IN:[1810..1812] of)
          (NP (CD:[1813..1814] 6) (SYM:[1815..1819] beta) (,:[1819..1820] ,)
              (CD:[1821..1822] 7) (NN:[1823..1837] beta-epoxy-CAN)))))
    (.:[1837..1838] .)))

;sentence 12 Span:1840..2058
;Inhibition of PC metabolism to 6 beta, 7 beta-epoxy-CAN by TAO and
;erythromycin,  and its induction by DEX and PCN, suggest involvement of Cyt
;P-450IIIA, which is  in turn inhibited by SP and 7 alpha-thio-spirolactone.
;[1854..1856]:substance:"PC"
;[1871..1895]:substance:"6 beta, 7 beta-epoxy-CAN"
;[1899..1902]:substance:"TAO"
;[1907..1919]:substance:"erythromycin"
;[1943..1946]:substance:"DEX"
;[1951..1954]:substance:"PCN"
;[1979..1992]:cyp450:"Cyt P-450IIIA"
;[2025..2027]:substance:"SP"
;[2032..2057]:substance:"7 alpha-thio-spirolactone"
(SENT
  (S
    (NP-SBJ
      (NP
        (NP (NN:[1840..1850] Inhibition))
        (PP (IN:[1851..1853] of)
          (NP (NN:[1854..1856] PC) (NN:[1857..1867] metabolism)))
        (PP (TO:[1868..1870] to)
          (NP (CD:[1871..1872] 6) (SYM:[1873..1877] beta) (,:[1877..1878] ,)
              (CD:[1879..1880] 7) (NN:[1881..1895] beta-epoxy-CAN)))
        (PP (IN:[1896..1898] by)
          (NP (NN:[1899..1902] TAO) (CC:[1903..1906] and)
              (NN:[1907..1919] erythromycin))))
      (,:[1919..1920] ,) (CC:[1922..1925] and)
      (NP
        (NP (PRP$:[1926..1929] its) (NN:[1930..1939] induction))
        (PP (IN:[1940..1942] by)
          (NP (NN:[1943..1946] DEX) (CC:[1947..1950] and) (NN:[1951..1954] PCN)))))
    (,:[1954..1955] ,)
    (VP (VBP:[1956..1963] suggest)
      (NP
        (NP (NN:[1964..1975] involvement))
        (PP (IN:[1976..1978] of)
          (NP
            (NP (NN:[1979..1982] Cyt) (NN:[1983..1992] P-450IIIA))
            (,:[1992..1993] ,)
            (SBAR
              (WHNP-1 (WDT:[1994..1999] which))
              (S
                (NP-SBJ-1 (-NONE-:[1999..1999] *T*))
                (VP (VBZ:[2000..2002] is)
                  (VP
                    (ADVP (IN:[2004..2006] in) (NN:[2007..2011] turn))
                    (VBN:[2012..2021] inhibited)
                    (NP-1 (-NONE-:[2021..2021] *))
                    (PP (IN:[2022..2024] by)
                      (NP-LGS
                        (NP (NN:[2025..2027] SP))
                        (CC:[2028..2031] and)
                        (NP (CD:[2032..2033] 7)
                            (NN:[2034..2057] alpha-thio-spirolactone))))))))))))
    (.:[2057..2058] .)))

;section 13 Span:2062..2106
;PMID: 8331551 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[2062..2066] PMID) (::[2066..2067] :) (CD:[2068..2075] 8331551)
        (NN:[2076..2077] -LSB-) (NNP:[2077..2083] PubMed) (::[2084..2085] -)
        (NN:[2086..2093] indexed) (IN:[2094..2097] for)
        (NNP:[2098..2106] MEDLINE-RSB-)))
